| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037837855 |
| P356 | DOI | 10.1007/S10120-015-0559-Z |
| P698 | PubMed publication ID | 26510663 |
| P50 | author | Yoshito Komatsu | Q87394566 |
| Astra M Liepa | Q95290974 | ||
| Atsushi Ohtsu | Q115365827 | ||
| Toshihiko Doi | Q80212852 | ||
| P2093 | author name string | Yasuhiro Shimada | |
| Hirofumi Yasui | |||
| Takao Tamura | |||
| Kohei Shitara | |||
| Masahiro Gotoh | |||
| Naotoshi Sugimoto | |||
| Tomohiro Nishina | |||
| Kei Muro | |||
| Taito Esaki | |||
| Kensei Yamaguchi | |||
| Shuichi Hironaka | |||
| Fumio Nagashima | |||
| Yoshihiko Segawa | |||
| Yasushi Omuro | |||
| Yukako Ichimiya | |||
| Kumari Chandrawansa | |||
| Seigo Yukisawa | |||
| Hansjochen Wilke | |||
| Michael Emig | |||
| P2860 | cites work | A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study) | Q80789086 |
| Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer | Q82931072 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | Q84078596 | ||
| The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 | ||
| Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies | Q35023481 | ||
| A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas | Q35586723 | ||
| Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study | Q36078921 | ||
| Disparities in gastric cancer chemotherapy between the East and West | Q36472210 | ||
| Geographic differences in approach to advanced gastric cancer: Is there a standard approach? | Q38114265 | ||
| Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) | Q42608504 | ||
| Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel | Q43056329 | ||
| Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
| Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). | Q45236674 | ||
| Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 | ||
| Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone | Q53384216 | ||
| Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an | Q57578399 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 927-938 | |
| P577 | publication date | 2015-10-28 | |
| P1433 | published in | Gastric Cancer | Q15724608 |
| P1476 | title | Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer | |
| P478 | volume | 19 |
| Q47269558 | A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. |
| Q64953700 | A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemother |
| Q39038994 | Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety |
| Q38815071 | Chemotherapy for advanced gastric cancer: future perspective in Japan |
| Q26741530 | Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma |
| Q94606068 | Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China |
| Q37342452 | Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience |
| Q33441654 | Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis |
| Q47921377 | Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial |
| Q38759129 | New agents on the horizon in gastric cancer |
| Q55527185 | New therapeutic options opened by the molecular classification of gastric cancer. |
| Q47402625 | Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. |
| Q52628875 | Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study |
| Q52672759 | Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label stud |
| Q38750633 | Second-line chemotherapy for patients with advanced gastric cancer. |
| Q48272934 | Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer |
| Q92408693 | Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies |
| Q28069924 | The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 |
| Q42265610 | The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated advanced gastric cancer: a network meta-analysis |
| Q38942944 | The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma |
| Q89953568 | Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial |
Search more.